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Dietary Omega Polyunsaturated Fatty Acid Intake 
and Patient- Reported Outcomes in Systemic Lupus 
Erythematosus: The Michigan Lupus Epidemiology and 
Surveillance Program
Prae Charoenwoodhipong,1 Sioban D. Harlow,1 Wendy Marder,1  Afton L. Hassett,1 W. Joseph McCune,1 
Caroline Gordon,2 Charles G. Helmick,3 Kamil E. Barbour,3 Lu Wang,1 Peter Mancuso,1 Emily C. Somers,1  and 
Suzanna M. Zick1
Objective. To examine associations between dietary intake of omega- 3 (n- 3; generally antiinflammatory) and 
omega- 6 (n- 6; generally proinflammatory) fatty acids and patient- reported outcomes in systemic lupus erythematosus 
(SLE).
Methods. This study was based on the population- based Michigan Lupus Epidemiology and Surveillance cohort. 
Estimates of n- 3 and n- 6 intake were derived from Diet History Questionnaire II items (past year with portion size 
version). Patient- reported outcomes included self- reported lupus activity (Systemic Lupus Activity Questionnaire 
[SLAQ]). Multivariable regression, adjusted for age, sex, race, and body mass index, was used to assess associations 
between absolute intake of n- 3 and n- 6, as well as the n- 6:n- 3 ratio, and patient- reported outcomes.
Results. Among 456 SLE cases, 425 (93.2%) were female, 207 (45.4%) were African American, and the mean ± 
SD age was 52.9 ± 12.3 years. Controlling for potential confounders, the average SLAQ score was significantly higher 
by 0.3 points (95% confidence interval [95% CI] 0.1, 0.6; P = 0.013) with each unit increase of the n- 6:n- 3 ratio. Both 
lupus activity and Patient- Reported Outcomes Measurement Information System (PROMIS) sleep disturbance scores 
were lower with each 1- gram/1,000 kcal increase of n- 3 fatty acids (SLAQ regression coefficient β = –0.8 [95% CI 
–1.6, 0.0]; P = 0.055; PROMIS sleep β = –1.1 [95% CI –2.0, –0.2]; P = 0.017). Higher n- 3 intakes were nonsignificantly 
associated with lower levels of depressive symptoms and comorbid fibromyalgia, and with higher quality of life, 
whereas results for the n6:n3 ratio trended in the opposite direction.
Conclusion. This population- based study suggests that higher dietary intake of n- 3 fatty acids and lower n- 6:n- 3 
ratios are favorably associated with patient- reported outcomes in SLE, particularly self- reported lupus activity and 
sleep quality.
INTRODUCTION
Systemic lupus erythematosus (SLE) is one of a number of 
rheumatic and musculoskeletal diseases (1) and is associated 
with substantial comorbidities, including renal impairment and 
premature cardiovascular disease (2,3). In general, advances 
in diagnosis and management have led to improved outcomes 
for patients with SLE (4). However, fatigue, poor sleep, chronic 
and often widespread pain, depression, and diminished quality 
of life remain challenging and prevalent issues for patients with 
SLE. As many as 85% of patients with SLE report significant lev-
els of persistent fatigue (5), 57% ongoing issues with sleep (6), 
75% depressive disorders (7), and >20% chronic pain pervasive 
enough to meet criteria for comorbid fibromyalgia (8). Nonphar-
macologic interventions that address these persistent symptoms 
could have a significant impact on quality of life for patients with 
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SLE. Modification of dietary polyunsaturated fatty acid (PUFA) 
intake could be one such approach.
Omega- 3 (n- 3) PUFA, found in fatty fish, nuts, seeds, and 
oils, and consumed at relatively low levels in the US diet, have 
been found to have antiinflammatory and immunomodulatory 
effects (9,10). In contrast, omega- 6 (n- 6) PUFA, including linoleic 
acid and arachidonic acid, are generally considered proinflamma-
tory (9,10) and are ubiquitous in the US food supply (e.g., corn 
and soybean oils) (11). Due to the uneven distribution of n- 6 and 
n- 3 fatty acids in the food supply, the ratio of n- 6:n- 3 consumption 
in the US is as high as 15:1 (11). The substantially higher intake 
of n- 6 fatty acids is thought to adversely impact health; products 
derived from n- 6 fatty acids include inflammatory eicosanoids (i.e., 
prostaglandin E2), as compared to eicosanoids derived from n- 3s, 
which are considered antiinflammatory substances (i.e., prosta-
glandin E3) (10–12). Because n- 6 and n- 3 compete for the same 
desaturation and elongation enzymes (13), both high absolute lev-
els of n- 6 consumption, as well as high ratios of n- 6 relative to n- 3, 
may contribute to a systemic proinflammatory state and immune 
dysfunction (13–15). Studies in lupus- prone mouse models have 
reported favorable effects associated with n- 3 fatty acid consump-
tion, including reduced levels of autoantibodies, proteinuria, and 
glomerulonephritis, as well as down- regulation of relevant CD4+ 
T cell–associated genes (16). An intriguing study found that dietary 
enrichment with the n- 3 fatty acid docosahexaenoic acid (DHA) in 
lupus- prone NZBWF1 mice suppressed crystalline silica–induced 
autoimmunity in a dose- response fashion, including inhibition of 
proinflammatory cytokines and reduced glomerulonephritis (17). 
However, precise mechanisms concerning PUFA- related immuno-
modulation and lupus outcomes require further elucidation.
Four human studies of n- 3 supplementation have reported 
improved lupus disease activity compared to placebo groups 
(18–21), while others have detected no differences (22–24). One 
of the clinical trials examined the impact of n- 3 supplementation 
on quality of life and common symptoms such as pain and fatigue 
in SLE and found trends toward improvement (21). However, 
studies in SLE have focused primarily on n- 3 supplementation, 
not dietary intake of fatty acids. In contrast to trials of individual 
supplements, measures of routine dietary intake allow for more 
comprehensive profiling of nutrient exposures (including n- 6 fatty 
acids and the n- 6:n- 3 ratio) and may reflect more stable or habit-
ual patterns of exposure over time.
We performed a cross- sectional study within the population- 
based Michigan Lupus Epidemiology and Surveillance (MILES) 
cohort, to assess the association between dietary intake of n- 3 
and n- 6 fatty acids and their ratio on patient- reported outcomes 
of SLE disease activity, quality of life, fatigue, pain, depression, 
and sleep. We anticipated that higher dietary intakes of n- 3 fatty 
acids and lower ratios of n- 6:n- 3 would be associated with more 
favorable patient- reported outcomes.
PATIENTS AND METHODS
Study population. This study was based on data from the 
MILES cohort, a population- based cohort of individuals with SLE 
from southeastern Michigan. Ethics approval was obtained from 
the institutional review boards of the University of Michigan and the 
Michigan Department of Health and Human Services, and cohort 
participants signed written, informed consent. Lupus cases for 
the MILES cohort were recruited from the MILES Surveillance 
Registry, one of the National US Lupus Registries supported by 
the Centers for Disease Control and Prevention and described 
elsewhere (2,25). Briefly, the MILES registry included individuals 
who were residents of Wayne or Washtenaw counties in Michigan 
(which encompass a source population of approximately 2.4 mil-
lion and include the cities of Detroit and Ann Arbor) during 2002–
2005, and with a new or existing diagnosis of SLE during this 
calendar period. Baseline enrollment for the MILES cohort was 
conducted between February 2014 and September 2015.
Baseline characteristic variables. Sociodemographic 
variables (e.g., race, ethnicity) were based on self- report. Height 
and weight were measured at the research clinic visit, and 
body mass index (BMI) was computed as weight divided by 
height squared (kg/m2).
Dietary assessment and omega fatty acid variables. 
Dietary intake was assessed using an abbreviated version of the 
Diet History Questionnaire II (DHQ II; past year version, with por-
tion size) (26) by the National Cancer Institute Epidemiology and 
Genomic Research Program, that focused on fatty foods (see 
Supplementary Table 1, available on the Arthritis Care & Research 
SIGNIFICANCE & INNOVATIONS
• This is the first study to show that lower dietary 
intake levels of omega-6 (proinflammatory) fatty 
acids and higher dietary intake levels of omega-3 
(antiinflammatory) fatty acids are favorably associ-
ated with patient-reported outcomes in lupus, in-
cluding decreased lupus activity and better sleep 
quality.
• The finding that dietary intake levels of omega-6 
and omega-3 fatty acids appeared to oppose one 
another, including after adjustment for omega-3 
supplement use (fish and/or flaxseed oil), suggests 
that use of supplements alone might be less like-
ly than a broader dietary approach to influence 
patient-reported outcomes in lupus.
• This study should prompt health care providers to 
consider reviewing the US Department of Agricul-
ture 2015–2020 Dietary Guidelines for Americans 
with their patients with systemic lupus erythemato-
sus to promote intake of fatty fish, nuts, and seeds, 
thereby encouraging a better balance of fatty acids 
from dietary sources.
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web site at http://onlin elibr ary.wiley.com/doi/10.1002/acr.23925/ 
abstract). Diet*Calc software, version 1.5.0 (27), was used to 
link dietary data to nutrient databases from the US Department 
of Agriculture (USDA) (for n- 6) and the Nutrition Data System for 
Research (NDSR) (for n- 3) for generation of nutrient intake esti-
mates (28). The Diet*Calc/NDSR n- 3 fatty acid variable repre-
sented the sum of the following fatty acids: alpha- linolenic acid 
(18:3n- 3), parinaric acid (18:4n- 3), eicosapentaenoic acid (EPA; 
20:5n- 3), docosapentaenoic acid (22:5n- 3), and DHA (22:6n- 3) 
(29). Omega- 6 was calculated as total octadecadienoic acid or 
linoleic acid (18:2n- 6).
Total n- 3 and n- 6 were adjusted for fat calorie intake (per 
1,000 kcal) to remove extraneous variation and control for con-
founding (30). The fat energy–adjusted n- 3 and n- 6 variables were 
used as independent variables in the multivariable models and to 
compute the n- 6:n- 3 ratio. While the dietary assessment did not 
include quantification of supplement use, omega- 3 supplements 
(fish oil and flaxseed oil) were recorded as yes/no if used more 
than once per week. Thus, in secondary models, we included 
omega- 3 supplement use as a binary covariate.
Patient- reported outcomes measures. Detailed socio-
demographic and patient- reported outcome data were collected 
at baseline and included the measures described below. The 
Systemic Lupus Activity Questionnaire (SLAQ) (31) was used to 
assess SLE disease activity. The SLAQ is a self- administered 
tool developed for epidemiologic studies and is not intended for 
clinical management. It includes 24 symptom questions and a 
numerical rating scale assessing disease activity during the past 
3 months. The SLAQ yields scores ranging from 0 to 47, with 
higher scores indicating greater disease activity.
The Survey Criteria for Fibromyalgia (FM Scale) (32) was used 
to assess the presence of fibromyalgia/widespread pain. The FM 
Scale consists of the widespread pain index that provides a count 
of the number of body regions reported as painful by the patient 
(range 0–19) and the symptom severity scale that assesses 
fatigue, nonrefreshing sleep, cognitive problems, and the extent of 
somatic symptoms (range 0–12). Based on the FM Scale, partic-
ipants were classified as fulfilling criteria for fibromyalgia if the fol-
lowing were met: widespread pain index ≥7 and symptom severity 
≥5, or widespread pain index of 3–6 and symptom severity ≥9; 
and with symptoms present at a similar level for at least 3 months 
in the absence of a disorder that would otherwise explain the pain.
The Patient- Reported Outcomes Measurement Informa-
tion System (PROMIS) depression short form, version 1.0, is an 
8- item measure used to assess self- reported negative mood, views 
of self, and social cognition, as well as positive affect and engage-
ment. Scores can range from 37.1 to 81.1, with higher scores rep-
resenting worse depressive symptoms (33). The PROMIS sleep 
disturbance short form, version 1.0, is an 8- item measure used 
to assess perception of sleep quality, which includes sleep depth 
and restoration associated with sleep. Scores range from 28.9 
to 76.5, with higher scores representing worse sleep disturbance 
(34).
The RAND Medical Outcomes Study Short Form 36 (SF- 36) 
instrument (35) was used to measure health- related quality of life 
(HRQoL). It is a self- report questionnaire consisting of 36 items 
aggregated to score 8 subscales related to physical and mental 
health. Subscales include physical functioning, role physical, 
bodily pain, general health, energy/fatigue, social function, 
role emotional, and mental health. The subscale scores are 
normalized for a mean ± SD of 50 ± 10; higher scores indicate 
better HRQoL.
The Lupus Quality of Life Questionnaire (LupusQoL) (36) was 
used to assess disease- specific quality of life. The LupusQoL is a 
Table  1. Baseline characteristics and patient- reported outcome 
scores among patients with systemic lupus erythematosus (n = 
456)*
Characteristic Value
Age, mean ± SD years 52.9 ± 12.3
Female, no. (%) 425 (93.2)
Race, no. (%)
White 235 (51.5)
African American 207 (45.4)
Asian 4 (0.9)
Other/unspecified 10 (2.2)
Hispanic ethnicity, no. (%) 17 (3.7)
Body mass index, mean ± SD kg/m2 30.0 ± 8.0
Fat energy intake, mean ± SD kcal 131.0 ± 151.4
Dietary n- 3 intake, grams/1,000 kcal 3.1 ± 0.9 (0.7–7.2)
Dietary n- 6 intake, grams/1,000 kcal 20.1 ± 7.5 (5.0–36.7)




SLAQ 13.0 ± 8.0 (0–38)
FM Scale positive, no. (%) 188 (41.2)
PROMIS depression 51.8 ± 9.9 (37.1–81.1)
PROMIS sleep disturbance 56.5 ± 8.8 (28.9–76.5)
SF- 36 subscales
Physical functioning 56.2 ± 30.2 (0–100)
Role functioning/physical 41. 8 ± 42.5 (0–100)
Role functioning/emotional 58.1 ± 43.5 (0–100)
Energy/fatigue 39.8 ± 21.9 (0–100)
Emotional/well- being 69.5 ± 19.2 (4–100)
Social functioning 64.3 ± 29.0 (0–100)
Pain 51.8 ± 27.0 (0–100)
General health 42.1 ± 23.8 (0–100)
LupusQoL domains
Physical health 65.0 ± 27.3 (0–100)
Pain 63.7 ± 28.6 (0–100)
Planning 74.4 ± 28.3 (0–100)
Intimate relationships 70.7 ± 33.7 (0–100)
Burden to others 65.5 ± 31.9 (0–100)
Emotional health 80.7 ± 20.0 (8.3–100)
Body image 74.8 ± 24.6 (0–100)
Fatigue 61.6 ± 26.5 (0–100)
* Values are the mean ± SD (range) unless indicated otherwise. 
Sample sizes for variables with >1% missing: Lupus Quality of 
Life Questionnaire (LupusQoL) intimate relationships (n = 392); 
LupusQoL body image (n = 402). SLAQ = Systemic Lupus Activity 
Questionnaire; FM Scale = Survey Criteria for Fibromyalgia; PROMIS = 
Patient- Reported Outcome Measurement Information System; 
SF- 36 = Medical Outcomes Study Short Form 36 instrument. 
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34- item scale, and scores are aggregated into 8 subscales includ-
ing physical health, emotional health, body image, pain, planning, 
fatigue, intimate relationships, and burden to others. Scores range 
from 0 to 100, with higher scores indicating better HRQoL.
Statistical analysis. Descriptive statistics were computed, 
with mean ± SD for continuous variables, and frequency and per-
centage for categorical variables. Univariate logistic or linear regres-
sion were performed for dichotomous and continuous outcomes, 
respectively, to examine the associations between fat energy–
adjusted fatty acid intake (n- 3, n- 6, and the ratio of n- 6:n- 3) and 
patient- reported outcomes. Outcomes for linear regression mod-
els were normally distributed. Separate models were constructed 
for each patient- reported outcome. Multivariable models were 
adjusted for covariates determined a priori to be relevant to the 
exposures and outcomes based on prior research (age, sex, race, 
and BMI in primary models; secondary models also included n- 3 
supplement use) (37–40). Effect estimates from the multivariable 
logistic models (odds ratios [ORs]) and linear regression models 
(beta coefficients, mean outcome changes associated with 1- unit 
change of the covariate) with 95% confidence intervals (95% CIs) 
are shown. Electronic data capture and management used the 
REDCap tools hosted at the University of Michigan (41). Statistical 
analysis was conducted using SPSS Statistics software, version 
23, and Stata software, version 14.
RESULTS
At the baseline visit, 462 lupus cases were enrolled, of whom 
456 completed the dietary questionnaire and were included in 
this study. Characteristics of the study population are shown in 
Table 1. Over 93% of the participants were female, average age 
was 53 years, and self- identified race was primarily white (52%) or 
African American (45%).
PUFA intake. The fat energy–adjusted dietary intake of 
n- 3 was mean ± SD 3.1 ± 0.9 grams/1,000 kcal (range 0.7–7.2). 
The mean n- 6 intake was mean ± SD 20.1 ± 7.5 grams/1,000 kcal 
(range 5.0–36.7). The mean ± SD n- 6:n- 3 ratio was 6.9 ± 2.9, with 
ratios ranging from 1.2 to 18.0. Use of flaxseed and/or fish oil sup-
plements was reported in 112 of 456 (26.8%) of the participants.
PUFA intake and patient- reported outcomes. Esti-
mated associations between PUFA intake and patient- reported 
outcomes from the primary models are shown in forest plots 
(Figures  1–4). These models were adjusted for sex, age, race, 
and BMI. Self- reported lupus disease activity was significantly 
associated with PUFA intake (Figure 1); for each unit increase in 
the ratio of n- 6:n- 3, the mean SLAQ score was correspondingly 
higher by 0.3 points (95% CI 0.1, 0.6; P = 0.013). Furthermore, 
an association between greater absolute n- 3 intake and reduced 
Figure 1. Associations between dietary polyunsaturated fatty acid 
intake (n- 3, n- 6, and ratio n- 6:n- 3) and patient- reported outcome 
measures for lupus activity (Systemic Lupus Activity Questionnaire 
[SLAQ]), sleep quality (Patient- Reported Outcomes Measurement 
Information System [PROMIS] sleep disturbance), and depression 
(PROMIS depression), from separate multivariable models. The 
circle, square, and triangle markers indicate regression (beta) 
coefficients, which represent mean outcome changes associated 
with each 1- unit increase of the respective polyunsaturated fatty 
acid variable; horizontal lines indicate 95% confidence intervals. 
Lower scores for the SLAQ and PROMIS measures indicate better 
outcomes (coefficients below 0 indicate favorable associations, 
and above 0 indicate unfavorable associations). The n- 3 and n- 6 
fatty acid variables were fat energy–adjusted (grams/1,000 kcal). 
Multivariable models were adjusted for the covariates sex, age, race, 
and body mass index. coeff = coefficient; DEPRESS = depression.
Figure  2. Associations between dietary fatty acid intake (n- 3, 
n- 6, and ratio n- 6:n- 3) and fulfillment of fibromyalgia (FM) survey 
criteria, from separate multivariable models. The circle, square, and 
triangle markers designate odds ratios (ORs), and horizontal lines 
indicate 95% confidence intervals. ORs below 1 indicate favorable 
associations, and above 1 indicate unfavorable associations. The n- 3 
and n- 6 fatty acid variables were fat energy–adjusted (grams/1,000 
kcal). Multivariable models were adjusted for the covariates sex, 
age, race, and body mass index.
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SLE activity bordered on significance, where for each unit increase 
of n- 3 intake, the SLAQ score was lower by 0.8 points (regression 
coefficient β = –0.8 [95% CI –1.6, 0.0]; P = 0.055). Cut points for 
clinically meaningful changes on the SLAQ have not been defined, 
but as a patient- reported outcome measure, scores represent 
activity perceptible to the patient and thus potentially meaningful 
from the patient perspective.
Perceived sleep quality (Figure 1) was also significantly asso-
ciated with PUFA intake, whereby each unit increase of n- 3 intake 
was associated with a lower mean PROMIS sleep disturbance 
score by –1.1 points (95% CI –2.0, –0.2; P = 0.017). However, the 
ratio of n6:n3 was not significantly associated with sleep distur-
bance (β = 0.2 [95% CI –0.1, 0.5]; P = 0.111). We did not detect 
significant associations for depression and PUFA intake (Figure 1) 
(n- 3 β = –0.9 [95% CI –1.9, 0.1]; P = 0.093; ratio n6:n3 β = 0.1 
[95% CI –0.2, 0.5]; P = 0.369).
We assessed 3 dimensions of pain: fibromyalgia/widespread 
pain as a dichotomous measure representing fulfillment of the FM 
Scale (Figure 2), the continuous pain subscales of the SF- 36 (Fig-
ure 3), and the LupusQoL (Figure 4). There were not significant 
associations between PUFAs and the 3 pain measures. However, 
there was an inverse association between n- 3 intake and comor-
bid FM that bordered on significance, such that with each unit 
increase of n- 3 intake, fulfillment of FM survey criteria was approx-
imately 20% lower (OR 0.82 [95% CI 0.66, 1.02]; P = 0.07).
For general and disease- specific quality of life measures (SF- 36 
and LupusQoL, respectively) (Figures 3 and 4), significant associa-
tions were not detected for any of the PUFA measures. However, 
a general trend was observed for the majority of subscales (14 of 
16), whereby higher n- 3 intakes were associated with higher sub-
scale scores, higher ratios of n- 6:n- 3 were negatively associated, 
and absolute n- 6 intake remained around a null association. For 
the SF- 36,  subscale scores that deviate from the mean of 50 
by 1 SD (SD = 10) are  generally thought to be clinically relevant. 
PROMIS measures  similarly are standardized with a mean of 50.
Secondary models were constructed including n- 3 supple-
ment use (flaxseed and/or fish oil), in addition to the other covari-
ates from the main models (see Supplementary Table 2, available 
on the Arthritis Care & Research web site at http://onlin elibr ary.
wiley.com/doi/10.1002/acr.23925/ abstract). There were no sub-
stantive changes to results. However, the association between 
absolute n- 3 intake and reduced SLE activity, which bordered on 
significance in the main model, now reached significance (β = –0.8 
[95% CI –1.7, 0.0]; P = 0.049).
DISCUSSION
In this population- based, cross- sectional study, lower ratios 
of n- 6 (proinflammatory) to n- 3 (antiinflammatory) fatty acids and 
higher levels of n- 3 fatty acid intake were significantly associated 
Figure 3. Associations between dietary fatty acid intake (n- 3, n- 6, 
and ratio n- 6:n- 3) and health-related quality of life, measured by the 
Medical Outcomes Study Short Form 36 (MOS SF- 36), from separate 
multivariable models. The circle, square, and triangle markers indicate 
regression (beta) coefficients, which represent mean outcome changes 
associated with each 1- unit increase of the respective polyunsaturated 
fatty acid variable; horizontal lines indicate 95% confidence intervals. 
Higher scores indicate better health- related quality of life. The n- 3 
and n- 6 fatty acid variables were fat energy–adjusted (grams/1,000 
kcal). Multivariable models were adjusted for the covariates sex, age, 
race, and body mass index. fx = functioning; coeff = coefficient. Color 
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Figure  4. Associations between dietary fatty acid intake (n- 3, n- 
6, and ratio n- 6:n- 3) and lupus- specific quality of life, measured 
by the Lupus Quality of Life Questionnaire (LQoL), from separate 
multivariable models. The circle, square, and triangle markers indicate 
regression (beta) coefficients, which represent mean outcome changes 
associated with each 1- unit increase of the respective polyunsaturated 
fatty acid variable; horizontal lines indicate 95% confidence intervals. 
Higher scores indicate better health- related quality of life. The n- 3 and 
n- 6 fatty acid variables were fat energy–adjusted (grams/1,000 kcal). 
Multivariable models were adjusted for the covariates sex, age, race, 
and body mass index. coeff = coefficient. Color figure can be viewed 
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with improved self- reported lupus disease activity. Higher levels of 
n- 3 intake were also significantly associated with better perceived 
sleep quality. Absolute intake levels of n- 6 fatty acids, without 
accounting for n- 3 fatty acid intake, were not independently asso-
ciated with any of the patient- reported outcomes.
Across the remaining outcomes of depression, fibromyalgia, 
pain, and HRQoL, although results did not reach statistical signif-
icance, the direction and magnitudes of association were gener-
ally consistent, in that increased n- 3 intake and decreased ratios 
of n- 6:n- 3 appeared favorable, whereas n- 6 intake alone hovered 
around a null association.
Our findings of associations between PUFA intake and 
patient- reported SLE disease activity are consistent with some 
prior studies in patients with SLE. A cross- sectional study of 
patients with SLE found that adipose tissue levels of EPA and 
DHA were negatively correlated with disease activity (42). A 
4- month open- label trial of fish oil supplementation (3 grams/
day) (20), as well as 3 approximately 6- month trials of fish oil 
supplementation (3–4.5 mg/day) versus olive oil placebo, found 
decreases in SLE activity (18,19,21). However, a 12- week trial of 
fish oil (3 grams/day) versus corn starch placebo (22) and 2 small 
trials (one in pediatric lupus, the other in lupus nephritis) failed 
to detect improvement in lupus activity (23,24). With the positive 
trials having intervention periods of approximately 4–6 months, 
shorter interventions may be insufficient to impact lupus activity. 
Notably, supplement trials are not directly comparable to studies 
of dietary intake, and n- 3 doses in clinical trials often exceed 
dietary intake levels (the average n- 3 dietary intake in our lupus 
population was 0.42 grams/day, unadjusted for energy intake).
In terms of HRQoL, one of the above referenced trials in 
SLE found that none of the SF- 36 subscales was significantly 
improved after 6 months of fish oil supplementation compared 
to placebo, though there were nonsignificant trends of improve-
ment in the energy/fatigue and emotional well- being subscales in 
the fish oil group compared to placebo group (21). We likewise 
observed nonsignificant associations of benefit in these domains.
Our finding of a small but significant association between 
n- 3 intake and sleep quality is compatible with findings from a 
study from coastal Ecuador, in which higher DHA blood levels and 
oily fish consumption were significantly associated with improved 
sleep quality (43). Another study in which male forensic patients 
were randomized to consumption of fatty fish versus meat 3 times 
per week for 6 months found significantly improved sleep and daily 
functioning in the fish group (44). Further, n- 3 levels in red blood 
cells have been found to be inversely associated with obstructive 
sleep apnea severity (45). Although the mechanisms of how n- 3 
fatty acids impact sleep quality are unclear, (43) such effects might 
be due to the role that n- 3s, particularly EPA and DHA, play in 
increasing serotonin secretion (46); low serotonin levels result in 
sleep disruption and sleep disorders, including insomnia.
There are several limitations in our study. First, the abbreviated 
dietary questionnaire that we used mainly captured PUFA intake 
from cooking oil, seafood, beans and eggs, which could under-
estimate absolute PUFA intake. Although cooking oils and marine 
products are the main dietary sources of n- 3 and n- 6, we were 
unable to capture data on PUFA intake from other sources such 
as leafy greens, nuts, seeds, and meat. Quantification of n- 3 sup-
plement use was not possible given the yes/no format for sup-
plements in the dietary questionnaire; however, we included n- 3 
supplement use as a binary variable in secondary models. Thus, 
we likely underestimated both n- 3 and n- 6, though underestimation 
of n- 6 was more likely given its greater presence in the food supply. 
The average n- 6:n- 3 ratio in our study population (roughly 7:1) is 
lower than that expected from the standard American diet (up to 
15:1) (11). In comparison, a larger cohort study in Detroit, Michigan 
of colorectal cancer cases and controls that used a food frequency 
questionnaire assessing the entire diet found the ratio of n- 6:n- 3 to 
be approximately 10:1 (47); while this result is higher than the ratio 
in our lupus population from the same region, it is still lower than 
typically reported for the US population. There is some evidence for 
a downward shift of n- 6:n- 3 in recent years due to increased use of 
canola oil (which is n- 3 rich) in the American food supply (9).
A second limitation is that the brief dietary questionnaire lim-
ited us from calculating a global measure of diet quality, or from 
estimating total energy intake from all the food groups that can be 
used for energy adjustment. The energy adjustment from only fat 
intake might overestimate the energy- adjusted absolute amount 
of PUFAs. Dietary questionnaires are also subject to recall bias 
and are less quantitative than biomarker measurements. How-
ever, a strength of dietary questionnaires is that they cover aver-
age intake over preceding months and not exposure at a single 
time point. Another limitation was that our outcome measure for 
lupus activity (SLAQ) was based on self- report. While this tool has 
been validated for epidemiologic research and is a preferred tool 
for self- reported lupus activity measurement, tools that incorpo-
rate rheumatologist assessment and laboratory findings are the 
gold- standard for use in a clinical setting.
Unfortunately, the clinician- centric tools are rarely feasible in 
epidemiologic field research. In addition, while we adjusted for 
potential confounders in multivariable models, unrecognized con-
founders may not have been accounted for, which would result 
in residual confounding. Finally, the cross- sectional nature of our 
study did not allow for exploration of temporality or causal effects 
of variations in PUFA intake on disease outcomes.
Future research should focus on examination of PUFA intake 
from all dietary sources and supplements and should also incor-
porate objective measurement of PUFAs in blood. More refined 
PUFA measurement would increase the accuracy and precision 
of estimated relationships between PUFA and outcomes in SLE. 
Randomized clinical trials of n- 3 rich diets are also warranted to 
assess causality.
In the absence of dietary trials manipulating PUFA levels in 
SLE, review of the USDA 2015–2020 Dietary Guidelines for Amer-
icans might be considered as part of patient education. These 
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guidelines recommend that adults eat at least 8 ounces of sea-
food per week, with a target intake of at least 250 mg per day 
of the omega- 3 fatty acids EPA and DHA. However, awareness 
of seafood advisories and US Food and Drug Administration/ 
Environmental Protection Agency advice on the best seafood 
choices should be included (48), so that species most likely to 
be contaminated with toxicants such as mercury can be avoided. 
While the seafood guidelines are targeted to children and women 
of reproductive age, they may also be of particular relevance to 
lupus and autoimmune populations, because even low- levels 
of methylmercury exposure (for which the primary route of expo-
sure is ingestion of contaminated seafood) have been associated 
with autoantibody positivity (49). Species of fish high in omega- 3 
and low in mercury include salmon and sardines. The USDA 
Dietary Guidelines also recommend consuming 1 oz per day 
(approximately one- fourth cup) of nuts and seeds, with particular 
emphasis on those high in n- 3s, such as flaxseeds, walnuts, and 
chia seeds, and shifting to canola oil in cooking (50). Adherence 
to the above guidelines would be expected to favorably shift per-
sonal n- 6:n- 3 ratios.
In conclusion, lower ratios of n- 6:n- 3 and higher absolute 
levels of n- 3 fatty acids in the diet of individuals with SLE were sig-
nificantly associated with lower self- reported lupus disease activity 
scores and with better sleep quality, and trended toward favorable 
associations with a range of patient- reported outcomes of clinical 
importance in SLE, including pain, depression, and quality of life. 
Given that treatment of lupus frequently requires multiple phar-
macologic agents, a nonpharmacologic intervention that could 
target various comorbidities is a particularly attractive prospect. 
Future studies are needed to help elucidate the mechanisms by 
which PUFAs impact outcomes in lupus, and to assess whether 
dietary manipulation of PUFAs can translate into clinically mean-
ingful disease control. In the meantime, nutritional education on 
omega- 3 rich seafood (low- mercury species), nuts, seeds, and 
seed oils may be beneficial for SLE patients.
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